Intravitreal lower- dose (20 mu g) melphalan for persistent or recurrent retinoblastoma vitreous seeds

Basit Öğe Kaydı
dc.authorid0000-0001-6090-4448
dc.contributor.authorTuncer, Samuray
dc.contributor.authorBalcı, Özlem
dc.contributor.authorTanyıldız, Burak
dc.contributor.authorKebudi, Rejin
dc.contributor.authorShields, Carol
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T20:02:15Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T20:02:15Z
dc.date.issued2015
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Göz Hastalıkları Ana Bilim Dalı
dc.descriptionWOS: 000378842200007
dc.descriptionPubMed ID: 26469234
dc.description.abstractBACKGROUND AND OBJECTIVE: The major cause of failure in the management of retinoblastoma is the persistence/recurrence of vitreous seeds (VS). This study reports the efficacy and complications of standard lower-dose (20 mu g) intravitreal melphalan for VS. PATIENTS AND METHODS: Retrospective review of all patients with active VS treated with lower-dose intravitreal melphalan (20 mu g/0.1 mL) on a monthly basis until complete VS regression was achieved. RESULTS: A total of 14 injections were delivered to seven eyes of seven patients (range: 1-4; median: 2). At a median follow-up of 20 months (range: 12-32 months), complete regression of VS was achieved in all cases (100%), and globe salvage was achieved in six cases (86%). One eye required enucleation for solid tumor recurrence. Side effects of retinal pigment epithelium mottling at the site of injection was noted in two eyes (29%). CONCLUSION: The 2-year results of this study suggest that standard lower-dose (20 mu g) intravitreal melphalan is safe and highly effective for the management of viable VS from retinoblastoma.
dc.identifier.citationTuncer, S., Balcı, Ö., Tanyıldız, B., Kebudi, R. ve Shields, C. (2015). Intravitreal lower- dose (20 mu g) melphalan for persistent or recurrent retinoblastoma vitreous seeds. Ophthalmic Surgery Lasers & Imaging Retina, 46(9), 942-948. https://dx.doi.org/10.3928/23258160-20151008-07
dc.identifier.doi10.3928/23258160-20151008-07
dc.identifier.endpage948
dc.identifier.issn2325-8160
dc.identifier.issn2325-8179
dc.identifier.issue9
dc.identifier.scopusqualityQ1
dc.identifier.startpage942
dc.identifier.urihttps://dx.doi.org/10.3928/23258160-20151008-07
dc.identifier.urihttps://hdl.handle.net/20.500.12511/3596
dc.identifier.volume46
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSlack Incorporated
dc.relation.ispartofOphthalmic Surgery Lasers & Imaging Retinaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectRetinoblastoma
dc.subjectIntravitreal Melphalan
dc.titleIntravitreal lower- dose (20 mu g) melphalan for persistent or recurrent retinoblastoma vitreous seeds
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu